Wang Xiaopeng, Ye Jingjing, Liu Daoning, Yan Liang, Li Shuquan, Lv Ang, Li Chengpeng, Wu Jianhui, Qiu Hui, Hao Chunyi
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital & Institute, Beijing, 100142, P. R. China.
Trauma Treatment Center, National Center for Trauma Medicine, Peking University People's Hospital, Key Laboratory of Trauma Treatment and Neural Regeneration (Peking University), Beijing, 100044, P. R. China.
J Cancer Res Clin Oncol. 2025 Jan 24;151(2):47. doi: 10.1007/s00432-025-06094-0.
Liposarcomas are mesenchymal malignant tumors characterized by varying degrees of adipocytic differentiation that comprises approximately 20% of soft tissue sarcomas. Despite advancements in this field, there remains a need for a comprehensive understanding of the mechanisms, diagnosis, and treatment of liposarcomas. Currently, there is a lack of bibliometric surveys on the development trajectory of liposarcomas treatment, research hotspots, and author and team collaboration.
In this study, we obtained publications from the Web of Science database from 2004 to 2023, with a specific focus on the treatment of liposarcomas. By utilizing bibliometric methods, the data were processed to facilitate visual analysis of various aspects, including authors, countries, institutions, cocitations, keywords, references, and gene characteristics.
The number of publications on liposarcomas treatment has increased over the past two decades, from 39 in 2004 to 232 in 2023, with the United States of America contributing the most publications. Among the institutions, the Memorial Sloan Kettering Cancer Center had the highest volume of 87 publications. Notably, Alessandro Gronchi published 63 articles on the treatment of liposarcomas in the last 20 years. Cancers is the journal with the highest number of 57 publications. High-frequency keywords in these publications included "soft tissue sarcoma", "liposarcoma", "retroperitoneal sarcoma", "surgery", "dedifferentiated liposarcoma", "trabectedin" and "radiotherapy". Recent trends, identified through strong citation bursts from 2020 to 2023, include next-generation sequencing, radiotherapy, and patient-derived cell lines. High-frequency genes in the liposarcomas treatment field include TP53, MDM2, CDK4, DDIT3, and CD274.
The treatment of liposarcomas has garnered increasing attention worldwide in the last 20 years. The treatment approach has shifted from surgical resection to multidisciplinary therapy. The molecular and biological characteristics of different tumor subtypes have attracted more research attention, providing an important reference for the choice of treatment. The findings of this study contribute to providing a comprehensive understanding of liposarcomas treatment among researchers. Moreover, they offer valuable perspectives that can guide future research.
脂肪肉瘤是间叶组织恶性肿瘤,其特征为不同程度的脂肪细胞分化,约占软组织肉瘤的20%。尽管该领域取得了进展,但仍需要全面了解脂肪肉瘤的发病机制、诊断和治疗方法。目前,缺乏关于脂肪肉瘤治疗发展轨迹、研究热点以及作者和团队合作情况的文献计量学调查。
在本研究中,我们从科学网数据库获取了2004年至2023年的出版物,特别关注脂肪肉瘤的治疗。通过运用文献计量学方法,对数据进行处理,以便对包括作者、国家、机构、共被引文献、关键词、参考文献和基因特征在内的各个方面进行可视化分析。
在过去二十年中,关于脂肪肉瘤治疗的出版物数量有所增加,从2004年的39篇增至2023年的232篇,其中美国发表的出版物数量最多。在各机构中,纪念斯隆凯特琳癌症中心发表的文章数量最多,为87篇。值得注意的是,亚历山德罗·格龙奇在过去20年中发表了关于脂肪肉瘤治疗的63篇文章。《Cancers》是发表文章数量最多的期刊,为57篇。这些出版物中的高频关键词包括“软组织肉瘤”“脂肪肉瘤”“腹膜后肉瘤”“手术”“去分化脂肪肉瘤”“曲贝替定”和“放射治疗”。通过2020年至2023年的强烈引用爆发确定的近期趋势包括下一代测序、放射治疗和患者来源的细胞系。脂肪肉瘤治疗领域的高频基因包括TP53、MDM2、CDK4、DDIT3和CD274。
在过去20年中,脂肪肉瘤的治疗在全球范围内受到越来越多的关注。治疗方法已从手术切除转向多学科治疗。不同肿瘤亚型的分子和生物学特征吸引了更多的研究关注为治疗选择提供了重要参考。本研究结果有助于研究人员全面了解脂肪肉瘤的治疗方法。此外,它们提供了宝贵的观点,可指导未来的研究。